Ischemia-Reperfusion Injury Research
Ischemia/Reperfusion (I/R) injury is defined as the cellular damage that results from a period of ischemia that is followed by the reestablishment of the blood supply to the infarcted tissue.Myocardial ischemia, also known as cardiac ischemia, is defined as the deprivation of oxygen and nutrients to the heart. This phenomenon occurs during a myocardial infarction, when an occlusive thrombus within a coronary artery prevents blood supply to the myocardium, but can also occur during cardiac surgery as a result of pharmacological intervention to temporarily stop the heart. Reperfusion restores blood supply to ischemic tissue, but this is paradoxically associated with further tissue damage.
Ischemia-Reperfusion Injury Research Products Targets
- Adenosine A2B Receptor (7)
- Adenosine A2A Receptor (11)
- Oxidative Phosphorylation (6)
- NHE (3)
- p53 (20)
- Inhibitor of Apoptosis (3)
- Caspase (9)
- Bcl-2 Family (13)
- Apoptosis Inducing (36)
- 14.3.3 Protein (1)
- Voltage-gated Sodium (NaV) Channel (30)
- Voltage-gated Potassium (KV) Channel (38)
- Others (7)
- Calcium-Sensing Receptor (4)
- Calcium Binding Protein Modulator (18)
- Epithelial Sodium Channel (3)
- Calpain (7)
- Adenosine A3 Receptor (8)
- Adenosine A1 Receptor (12)
- ASK1 (2)
- Acid-Sensing Ion Channel (3)
- Calcium-Activated Potassium (KCa) Channel (19)
- Calcium-Sensitive Protease Modulator (12)
- Inward Rectifier Potassium (Kir) Channel (21)
- NCX (5)
- Mitochondrial Permeability Transition Pore (3)
- Mitochondrial Calcium Uniporter (1)
- Ca2+-ATPase (7)
Products for Ischemia-Reperfusion Injury Research - Page 27
- Cat.No. Product Name Information/Activity
-
BCC6103
ProTx II
ProTx II is a selective blocker of Nav1.7 sodium channels with an IC50 of 0.3 nM, and is at least 100-fold selective for Nav1.7 over other sodium channel subtypes. ProTx-II inhibits sodium channels by decreasing channel conductance and shifting activation to more positive potentials and blocks action potential propagation in nociceptors.
-
BCC6906
QX 222
5369-00-6
-
BCC6889
QX 314 bromide
QX-314 bromide is a membrane-impermeable permanently charged sodium channel blocker.
-
BCC7326
QX 314 chloride
QX-314 chloride is a membrane-impermeable permanently charged sodium channel blocker.
-
BCC7844
Ralfinamide mesylate
Ralfinamide mesylate (FCE-26742A mesylate) is an orally available Na+ channel blocker derived from α-aminoamide, with function of suppressing pain.
-
BCC7847
Sipatrigine
Sipatrigine, a neuroprotective agent, is a glutamate release inhibitor, voltage-dependent sodium channel and calcium channel inhibitor, penetrating the central nervous system. Has potential to treat focal cerebral ischemia and stroke.
-
BCC6179
TC-N 1752
1211866-85-1
-
BCN1035
Tetrodotoxin
Tetrodotoxin is a highly selective <b>sodium channel</b> blocker, with <b>IC<sub>50</sub></b> of 33 nM for <b>Nav1.6</b>.
-
BCC2156
Valproic acid sodium salt (Sodium valproate)
Valproic acid sodium salt (Sodium Valproate) is an HDAC inhibitor, with IC50 in the range of 0.5 and 2 mM, also inhibits HDAC1 (IC50, 400 μM), and induces proteasomal degradation of HDAC2. Valproic acid sodium salt activates Notch1 signaling and inhibits proliferation in small cell lung cancer (SCLC) cells. Valproic acid sodium salt is used in the treatment of epilepsy, bipolar disorder and prevention of migraine headaches.
-
BCN2609
Vinpocetine
Vinpocetine (Ethyl apovincaminate) is a derivative of the alkaloid Vincamine that blocks voltage-gated Na+ channels. The IC50 value of Vinpocetine on direct IKK inhibition in the cell-free system is 17.17 μM. Vinpocetine is a phosphodiesterase (PDE) inhibitor and inhibits NF-κB-dependent inflammatory responses by directly targeting IκB kinase complex (IKK), and has been widely used for the treatment of cerebrovascular disorders.


